• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Tyra Biosciences Inc.

    4/17/26 8:10:01 AM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TYRA alert in real time by email
    DEFA14A 1 d86382ddefa14a.htm DEFA14A DEFA14A
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    (Amendment No.  )

     

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material under §240.14a-12

    Tyra Biosciences, Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment of Filing Fee (Check all boxes that apply):

     

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11

     

     
     


    LOGO

    P.O. BOX 8016, CARY, NC 27512-9903 Your vote matters! Meeting Materials: Notice of Meeting, Proxy Statement and Annual Report on Form 10-K Important Notice Regarding the Availability of Proxy Materials for the Stockholders Tyra Biosciences, Inc. Meeting to be held on May 28, 2026 For Stockholders of record as of April 2, 2026 Annual Meeting of Stockholders To order paper materials, use one of the Thursday, May 28, 2026 10:00 AM, Pacific Time The Annual Meeting will be held live via webcast—Please visit www.proxydocs.com/TYRA for following methods. more details. Internet: For a convenient way to view proxy materials, VOTE, and obtain www.investorelections.com/TYRA directions to attend the meeting go to www.proxydocs.com/TYRA To vote your proxy while visiting this site, you will need the 12 digit control number in the box below. Call: 1-866-648-8133 This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. This is not a ballot. You cannot use this notice to vote your shares. We encourage you to access and review all of the important information contained in the proxy materials before voting. Email: [email protected] Under United States Securities and Exchange Commission rules, proxy materials do not have to be delivered in paper. Proxy materials can be distributed by making them available on the * If requesting material by e-mail, please send a blank e-mail with the internet. 12 digit control number (located below) in the subject line. No other requests, instructions OR other inquiries should be included with your If you want to receive a paper or e-mail copy of the proxy materials, you must request one. e-mail requesting material. There is no charge to you for requesting a copy. In order to receive a paper package in time for this year’s meeting, you must make this request on or before May 18, 2026. Your control number Have the 12 digit control number located in the box above available when you access the website and follow the instructions. SEE REVERSE FOR FULL AGENDA Copyright © 2026 BetaNXT, Inc. or its affiliates. All Rights Reserved


    LOGO

    Tyra Biosciences, Inc. Annual Meeting of Stockholders THE BOARD OF DIRECTORS RECOMMENDS A VOTE: FOR ON PROPOSALS 1 AND 2 PROPOSAL 1. To elect three directors to serve as Class II directors for a three-year term expiring at the 2029 Annual Meeting of Stockholders and until their respective successors shall have been duly elected and qualified. 1.01 Habib J. Dable 1.02 Susan Moran, M.D., M.S.C.E. 1.03 Robert More 2. To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2026. 3. To transact such other business as may properly come before the Annual Meeting or any continuation, postponement or adjournment of the Annual Meeting.

    Get the next $TYRA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TYRA

    DatePrice TargetRatingAnalyst
    4/15/2026$54.00Buy
    Guggenheim
    4/6/2026$50.00Buy
    Canaccord Genuity
    2/24/2026Overweight
    Cantor Fitzgerald
    2/10/2026Outperform
    William Blair
    1/28/2026$59.00Overweight
    Barclays
    9/3/2025$35.00Strong Buy
    Raymond James
    5/21/2025$33.00Overweight
    Piper Sandler
    1/7/2025$28.00Buy
    UBS
    More analyst ratings

    $TYRA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Tyra Biosciences with a new price target

    Guggenheim initiated coverage of Tyra Biosciences with a rating of Buy and set a new price target of $54.00

    4/15/26 8:10:45 AM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity initiated coverage on Tyra Biosciences with a new price target

    Canaccord Genuity initiated coverage of Tyra Biosciences with a rating of Buy and set a new price target of $50.00

    4/6/26 8:46:04 AM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Tyra Biosciences

    Cantor Fitzgerald initiated coverage of Tyra Biosciences with a rating of Overweight

    2/24/26 7:56:45 AM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYRA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors

    -Seasoned biopharmaceutical leader brings deep commercial and strategic expertise to support TYRA's next phase of growth-CARLSBAD, Calif., April 17, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the appointment of Habib Dable to its Board of Directors.Mr. Dable brings more than 30 years of leadership experience across the global biopharmaceutical industry, including deep expertise in building and scaling blockbuster franchises and guiding companies through transformative growth."As TY

    4/17/26 8:00:00 AM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights

    - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -- Interim Ph2 data readouts on track: SURF302 expected by end of 1H'26 and BEACH301 in 2H '26 -- Cash, cash equivalents and marketable securities of $256.0 million at Q4 2025; runway through at least 2027 -CARLSBAD, Calif., March 2, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the fourth quarter and full-year ended Dece

    3/2/26 4:05:00 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tyra Biosciences Announces Poster Presentations at the 2026 ASCO® Genitourinary (GU) Cancers Symposium

    CARLSBAD, Calif., Feb. 23, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that two abstracts have been accepted for presentation at the 2026 ASCO® Genitourinary (GU) Cancers Symposium (ASCO GU). The meeting is being held February 26-28, 2026, in San Francisco, California.Details of the poster presentations are below:Title: "ctDNA monitoring of FGFR3-altered metastatic urothelial cancer treated with dabogratinib (formerly TYRA-300) in the SURF301 trial"Abstract Number: 809Session: Poste

    2/23/26 5:30:00 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYRA
    SEC Filings

    View All

    SEC Form DEFA14A filed by Tyra Biosciences Inc.

    DEFA14A - Tyra Biosciences, Inc. (0001863127) (Filer)

    4/17/26 8:10:01 AM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form DEF 14A filed by Tyra Biosciences Inc.

    DEF 14A - Tyra Biosciences, Inc. (0001863127) (Filer)

    4/17/26 8:08:11 AM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Tyra Biosciences Inc.

    8-K - Tyra Biosciences, Inc. (0001863127) (Filer)

    4/17/26 8:02:10 AM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYRA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Rueb Yuliya

    3 - Tyra Biosciences, Inc. (0001863127) (Issuer)

    4/2/26 4:38:16 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Kaplan Gilla

    4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

    3/27/26 4:44:50 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Fuhrman Alan was granted 1,376 shares, increasing direct ownership by 9% to 16,164 units (SEC Form 4)

    4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

    3/17/26 4:59:04 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYRA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Ra Capital Management, L.P. bought $1,664,700 worth of shares (163,287 units at $10.19) (SEC Form 4)

    4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

    6/16/25 8:06:50 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. bought $1,904,002 worth of shares (186,850 units at $10.19) (SEC Form 4)

    4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

    6/11/25 7:44:50 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Ra Capital Management, L.P. bought $11,751,304 worth of shares (1,211,198 units at $9.70) (SEC Form 4)

    4 - Tyra Biosciences, Inc. (0001863127) (Issuer)

    6/6/25 4:43:19 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYRA
    Leadership Updates

    Live Leadership Updates

    View All

    Tyra Biosciences Announces Appointment of Habib Dable to its Board of Directors

    -Seasoned biopharmaceutical leader brings deep commercial and strategic expertise to support TYRA's next phase of growth-CARLSBAD, Calif., April 17, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced the appointment of Habib Dable to its Board of Directors.Mr. Dable brings more than 30 years of leadership experience across the global biopharmaceutical industry, including deep expertise in building and scaling blockbuster franchises and guiding companies through transformative growth."As TY

    4/17/26 8:00:00 AM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tyra Biosciences Strengthens Leadership Team with Appointments of Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer

    CARLSBAD, Calif., Dec. 1, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today the appointment of two key members of its leadership team: Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer.  Together, Mr. Ashar and Ms. Faulds will be essential in advancing oral dabogratinib through global Phase 2 studies in skeletal dysplasia and urologic cancers and preparing for potential future pivotal Phase 3 studies. Mr. Ashar's appointment is effective immediately a

    12/1/25 8:00:00 AM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tyra Biosciences Announces Appointment of Adele Gulfo to Board of Directors

    CARLSBAD, Calif., Jan. 29, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today the appointment of Adele Gulfo to its Board of Directors. Ms. Gulfo brings nearly three decades of executive leadership experience to the TYRA board, with a strong track record in developing and commercializing some of the world's best-selling medicines at Pfizer, AstraZeneca, Viatris and Sumitomo Pharma. "Adele is one of the most accomplished drug developers in our industry, with nearly thirty years of global ex

    1/29/25 4:05:00 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYRA
    Financials

    Live finance-specific insights

    View All

    Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)

    - Encouraging preliminary anti-tumor activity observed in heavily pre-treated population - - At ≥ 90 mg QD, 6 out of 11 (54.5%) patients with FGFR3+ mUC achieved a confirmed partial response (PR), with 100% disease control rate and sustained duration of activity - - Positive safety results across all QD doses, with infrequent FGFR2/FGFR1-associated toxicities - - Conference call scheduled for October 25th, 2024, at 8AM EDT - CARLSBAD, Calif., Oct. 24, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, ann

    10/24/24 6:21:00 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ET

    CARLSBAD, Calif., Oct. 23, 2024 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that it will host a conference call and webcast on October 25, 2024 at 8:00 am ET to share interim clinical results of TYRA-300 from the SURF301 Phase 1/2 study in metastatic urothelial cancer (mUC). These data will be presented in a late-breaking oral presentation at the 36th EORTC-NCI-AACR (ENA) Symposium on Molecular Targets and Cancer Therapeutics, being held October 23-25, 2024, in Barcelona, Spain. Gary Ste

    10/23/24 4:05:00 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Tyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into Achondroplasia

    - In preclinical models, TYRA-300 demonstrated significant increases in growth and bone length- -Phase 2 clinical study for pediatric achondroplasia planned to be initiated in 2024--Conference call and webcast today, March 1st, at 8:00 am ET- CARLSBAD, Calif., March 1, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (NASDAQ:TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptors (FGFR) biology, today announced that it is expanding development of TYRA-300 into achondroplasia (ACH) based on positive preclinical results demonstrated in a study performed in collaboration with the Ima

    3/1/23 7:00:00 AM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TYRA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Tyra Biosciences Inc.

    SC 13D/A - Tyra Biosciences, Inc. (0001863127) (Subject)

    12/6/24 9:30:49 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Tyra Biosciences Inc.

    SC 13D/A - Tyra Biosciences, Inc. (0001863127) (Subject)

    11/19/24 9:31:34 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Tyra Biosciences Inc.

    SC 13G/A - Tyra Biosciences, Inc. (0001863127) (Subject)

    11/14/24 5:47:01 PM ET
    $TYRA
    Biotechnology: Pharmaceutical Preparations
    Health Care